GLP-1 agonists mimic this hormone, improving blood sugar levels, slowing the movement of food from the stomach into the small intestine, and helping you feel satiated
Originally developed for type 2 diabetes, it has proven effective in promoting weight loss and is now approved for this purpose as well
The mentioned potential benefits hold true in general for any transdermal delivery system and not GLP- patches specifically, as these still lack real-world evidence
Retatrutide is currently undergoing clinical trials and is not yet FDA approved, so its availability is limited to research settings
It includes GLP-1 receptor activity, but unlike semaglutide, it is a triple agonist, also targeting GIP and glucagon receptors for broader metabolic effects
The so-called GLP-1 patches available in the market containing herbal ingredients, may seem like a convenient option for weight management or diabetes control, but scientific evidence supporting their effectiveness is still limited